In vitro activity of ceftaroline and ceftobiprole against clinical isolates of Gram-positive bacteria from infective endocarditis: are these drugs potential options for the initial management of this disease?

Diagn Microbiol Infect Dis. 2020 Dec;98(4):115153. doi: 10.1016/j.diagmicrobio.2020.115153. Epub 2020 Jul 28.

Abstract

The in vitro activity of ceftaroline and ceftobiprole was assessed against 77 Gram-positive bacterial isolates recovered from patients diagnosed with infective endocarditis (IE). Our data confirm that these drugs are highly in vitro active against the most common agents of IE including methicillin-resistant Staphylococcus aureus, methicillin-resistant coagulase-negative staphylococci, and Streptococcus spp., with no significant differences between them. Also, ceftaroline and ceftobiprole have demonstrated a good activity against Enterococcus faecalis (MIC90 0.75 μg/mL and 0.5 μg/mL, respectively). The spectrum of these drugs together with the in vitro and in vivo data on them related with IE published in the scientific literature places them as potential options for the initial management of this disease.

Keywords: Ceftaroline; Ceftobiprole; Infective endocarditis.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Ceftaroline
  • Cephalosporins / pharmacology*
  • Endocarditis, Bacterial / microbiology*
  • Gram-Positive Bacteria / classification
  • Gram-Positive Bacteria / drug effects*
  • Gram-Positive Bacteria / isolation & purification
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • ceftobiprole